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Objectives: to assess the effect of treatment with mesoglycan, a sulphated polysaccharide compound, on the healing of
venous ulcers.
Design: randomised, placebo-controlled, double-blind, multicentre trial.
Methods: non-diabetic outpatients with chronic venous insufficiency confirmed by duplex ultrasound, normal ankle/arm
pressure index and presence of a leg ulcer were eligible. Patients were randomised to mesoglycan, 30 mg/day intramuscularly
for 3 weeks followed by 100 mg/day orally, or matching placebo, as an adjunct to compression therapy and topical wound
care. Treatment and observation were continued until complete ulcer healing or for 24±1 weeks. Time to ulcer healing
and healing rates were estimated with the Kaplan–Meier method.
Results: One hundred and eighty-three patients were randomised and included in the analysis (92 mesoglycan, 91
placebo). Median ulcer area upon inclusion was 3.6 cm2 in the mesoglycan group and 3.9 cm2 in the placebo group. The
estimated time to heal 75% of the patients was 90 days on mesoglycan versus 136 days on placebo, while the cumulative
rate of healing by the end of observation was 97% versus 82%, respectively. The difference in favour of mesoglycan was
statistically significant (p<0.05, centre-stratified Cox’s model). The relative risk of ulcer healing with mesoglycan
was 1.48. The rate of adverse events was 7/92 on mesoglycan and 6/91 on placebo.
Conclusions: treatment with mesoglycan in addition to established venous ulcer therapy resulted in a significantly faster
and more frequent ulcer healing, and did not raise any safety concerns.
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Introduction Mesoglycan is a sulphated polysaccharide com-
pound commercially available in some European
Chronic venous insufficiency (CVI) and ulceration rep- countries, both in a parenteral and oral form, for
resents an important medical problem because of its the treatment of vascular disease with an associated
prevalence (0.3% of the adult Western population), thrombotic risk. Mesoglycan is extracted from porcine
poor healing (20% of the ulcers remain open after 2 intestinal mucosa and is composed of heparan sulphate
years while the annual recurrence rate is 6 to 15%), (52%), dermatan sulphate (35%), electrophoretically
and healthcare costs.1 Since the underlying CVI cannot slow-moving heparin (8%) and chondroitin sulphate
be cured, therapy of venous ulcers is mainly aimed at (5%). Heparan and dermatan sulphate are thrombin
counteracting (by limb compression) or eliminating inhibitors acting through complementary pathways,
(by surgery) the transmission of increased venous i.e. antithrombin III and heparin cofactor II, respect-
pressure to the skin. Several systemic drug treatments ively.2,3 Mesoglycan and/or its major components have
have been tested for a possible effect on venous ulcer been shown to inhibit neutrophil adhesion and ac-
healing, but none has been widely accepted as standard tivation,4 to decrease capillary permeability,5 to en-
therapy in this setting.1 hance systemic fibrinolysis in humans,6 and to prevent
venous thrombus formation in experimental and clin-
ical settings.7–9 These properties may be relevant to the
∗ Please address all correspondence to: E. Arosio, Divisione di proposed pathogenic mechanisms for venous ulcer-
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formation of pericapillary fibrin cuffs.10 Oral ab- Randomisation and treatments
sorption of mesoglycan and dermatan sulphate
fractions has previously been demonstrated.11,12 Symp- Prior to study start, a computer-generated random-
isation list was prepared for each centre using balancedtomatic benefits of mesoglycan in CVI have been re-
ported in earlier small-scale studies.13,14 blocks of 4 patients. Mesoglycan (Prisma, Mediolanum
Farmaceutici, Milan, Italy; 30 mg/1 ml ampoules andThe present controlled trial was aimed at assessing
the effect of adjunct treatment with mesoglycan on 50 mg capsules) or placebo (matching saline solution
ampoules and excipient capsules) were packaged ac-the healing of chronic venous ulcers managed with
compression therapy and topical wound care. Patients cording to the lists in consecutively numbered con-
tainers. At each centre, treatment containers werewere observed until complete ulcer healing or for 24
weeks. assigned to patients according to their chronological
order of enrolment. Centres were also provided with
sealed envelopes to reveal individual treatment in case
of an emergency. These were retrieved and checked for
Patients and Methods integrity at the end of study. Otherwise, all personnel
involved in study implementation remained unaware
This was a randomised, parallel-group, placebo- of treatment assignation until the final data analysis.
controlled, double-blind, multicentre study. Random- Treatment with mesoglycan or placebo was initiated
isation to mesoglycan or placebo was stratified by intramuscularly with one ampoule once daily for 3
centre. The study was conducted at the outpatient weeks, and continued orally with one capsule twice
clinics of 18 Italian hospital departments of vascular daily.
or general surgery (n=12), angiology (n=4) and der- Compression therapy and topical wound care were
matology (n=2). The study protocol and patient in- applied to all patients. Permitted materials for com-
formation were approved by the ethics committee of pression therapy were short stretch elastic bandages
each centre. and zinc oxide elastic or non-elastic bandages. Other
components of ulcer dressing (gauzes, ointments) were
used at the investigator’s discretion. Wound care con-
sisted of regular ulcer cleansing with saline and local
Patients antiseptics. Lifestyle and postural instructions to re-
lieve venous hypertension were given to all patients.
Ambulatory patients with previous history and current Concomitant treatments with anticoagulant agents,
clinical diagnosis of CVI were eligible if the following prostanoids, vasoactive drugs or long-term aspirin
criteria were met: age, 18 to 80 years; duplex ultra- were prohibited.
sound evidence of CVI; ankle/arm arterial pressure
index at rest >0.90 on both limbs; presence of a leg
skin ulcer for less than one year, with maximum
orthogonal ulcer diameters having a product between Patient observation
4 and 20 cm2; ability to frequent the study centre;
and written informed consent. In the patients having Upon inclusion, the contours of the target ulcer were
drawn on a standard transparent sheet (OpSite Flexi-multiple skin lesions, the largest ulcer meeting the
required size was chosen as the target for the purpose grid, Smith & Nephew Medical, Hull, U.K.). Patients
were requested to assess ulcer-associated pain and toof the study.
Exclusion criteria comprised: diabetes mellitus; fill in the Medical Outcomes Study Short Form-36
(SF-36), a generic questionnaire for self-assessment ofother concomitant conditions possibly causing ulcera-
tion (e.g. blood dyscrasias, neuropathy, vasculitis); health-related quality of life,15 and underwent baseline
laboratory tests.active infection of the target ulcer; saphenectomy or
sclerotherapy scheduled for the coming 6 months; After treatment initiation, patients were followed-up
by fixed visits every 3 weeks, plus any supplementaryneed for treatment with heparin, oral anticoagulants,
prostanoids, vasoactive drugs or long-term aspirin; visits needed to renew compression and topical ther-
apies. Randomised treatment and patient observationactive bleeding; potential bleeding from organic
lesions; prothrombin activity <50%; platelet count were terminated when complete healing of the target
ulcer was ascertained by the investigator, or upon the<100×103 l; renal insufficiency (creatinine >2 mg/dl);
known intolerance to sulphated polysaccharides; and final visit scheduled at the end of week 24 (±1 week).
Ulcer-associated pain was recorded at each fixed visit.pregnancy.
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The SF-36 questionnaire was repeated at the end of significance level was 0.05 (two-tailed) and statistical
power was 0.80.observation. Laboratory tests were repeated at week
3 visit and at the end of observation. Adverse events Statistical analysis was performed using SAS System
software (SAS Institute, Cary, NC, U.S.A.). Time towere recorded irrespective of their presumed re-
lationship to study treatment. healing was estimated from Kaplan–Meier curves for
cumulative ulcer healing over time; treatment groups
were compared using Cox’s model, including baseline
ulcer area as a covariate. Relative risk for healing with
Assessments mesoglycan compared to placebo was derived from
Cox’s model after checking for proportionality of haz-
The primary end-point for efficacy was time to healing ards. As some patients did not actually heal by week
of the target ulcer, based upon the actual dates of 24±1, or were lost to follow-up, the relevant observa-
randomisation and of the visit (be it fixed or sup- tions were censored at the actual date of the last
plementary) when complete ulcer epithelialisation was available visit. Hence all randomised patients were
observed. The time-course of ulcer-associated pain was included in the analysis. The effect of treatment on
a secondary efficacy variable. Data from SF-36 were pain scores over time was tested by repeated-measures
used to assess the impact of ulcer healing, irrespective analysis of variance in the patients completing ob-
of treatment, on health-related quality of life. servation. Data from SF-36 were handled according to
Duplex ultrasound evidence of CVI was defined as published guidelines.15,18 The influence of ulcer healing
presence of (a) valvular incompetence and/or reflux on SF-36 scores was tested by analysis of covariance
at the sapheno-femoral or sapheno-popliteal junctions; (end-of observation scores corrected for baseline
and/or (b) vessel wall or valve morphologic altera- scores) in the patients completing observation. All
tions, endoluminal obstruction or reflux in the deep randomised patients were assessed for adverse events.
vein system. Concomitant incompetence of perforating All analyses were centre-stratified. Significance tests
veins was recorded when present. Baseline ankle/arm were two-tailed. No interim analysis was planned or
index was determined according to current guide- executed.
lines.16 Baseline ulcer areas were calculated from con-
tour sheets at a central location by computerised
Resultsplanimetry, using digital scanning and Analytica-Lite
3.0 software (Immagini & Computer, Bareggio, Italy).
From April to October 1999, 183 patients were includedUlcer-associated pain was assessed on a visual-ana-
in the study and randomised to mesoglycan (n=92)logue chromatic scale from 0 to 10.17 SF-36 was used
or placebo (n=91). As shown in Table 1, treatmentin a validated Italian version.18 For each of 8 health
groups were balanced for baseline characteristics in-domains explored, SF-36 produces a score from 0 to
cluding demographics, clinical history and duplex100 (the higher the score, the better the perceived
ultrasound findings relevant to CVI, target ulcer areahealth status). Adverse events that were fatal, life-
and duration, concomitant conditions and type ofthreatening, or involved hospitalisation or persistent
compression therapy adopted upon inclusion. Ulcersor significant disability were classified as ‘‘serious’’.19
of very recent onset (less than one month before in-Laboratory tests included activated partial throm-
clusion) were only present in 3 patients.boplastin time (APTT), complete blood count and
Patients completing observation were 168. Of these,blood chemistry (fibrinogen, renal and liver function
82 on mesoglycan and 69 on placebo achieved healingtests).
of the target ulcer, while 4 on mesoglycan and 13 on
placebo had still not healed by the end of week 24±1.
The mean duration of observation in study completers
was 70 days on mesoglycan and 87 days on placebo.Sample size and statistical analysis
The remaining 15 patients were lost to follow-up before
healing was achieved, due to their decision to with-The study sample was set at 90 patients per group to
ensure that of at least 70 per group were fully as- draw from the study (4 patients on mesoglycan, 6 on
placebo) or following an adverse event (2 and 3sessable. This number was estimated20 by assuming
that all patients would achieve ulcer healing by the patients, respectively). The individual treatment code
was only opened in one case. Development of ulcerend of week 24±1, and that mean (SD) time to healing
would be 84 (42) days in the placebo group and 63 infection at any time during observation was reported
in 6 mesoglycan and 4 placebo patients.(42) days in the mesoglycan group. The specified
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Table 1. Baseline patient characteristics.
Mesoglycan Placebo
(n=92) (n=91)
Female sex, n (%) 67 (73) 61 (67)
Age, years, mean (SD) 62 (12) 62 (11)
Clinical history
Venous thromboembolism, n (%) 22 (24) 27 (30)
Years from onset of CVI symptoms, median (IQR) 4.7 (0.5–17.0) 5.6 (0.8–19.4)
Surgery for CVI∗, n (%) 13 (14.1) 22 (24.2)
Sclerotherapy, n (%) 11 (12.0) 11 (12.1)
Duplex ultrasound findings§
Superficial vein valvular incompetence, n 87 85
Sapheno–femoral or sapheno–popliteal reflux, n 72 70
Incompetent perforating veins, n 63 70
Deep vein morphologic alterations¶, n 24 29
Reflux in deep veins, n 33 40
Target ulcer
Months from ulcer appearance, median (IQR) 3 (2–6) 3 (1—7)
Ulcer area, cm2, median (IQR) 3.6 (2.5–7.0) 3.9 (2.8–7.8)
Associated pain, 0–10 scale, mean (SD) 4.5 (3.0) 4.3 (2.8)
Concomitant conditions
Concomitant venous ulcer, n (%) 12 (13.0) 7 (7.7)
Arterial hypertension, n (%) 28 (30.4) 24 (26.4)
Obesity (body mass index [30), n (%) 27 (29.3) 22 (24.4)
Lower limb functional limitation, n (%) 4 (4.3) 4 (4.4)
Current smoking, n (%) 11 (12.0) 16 (17.6)
Abnormal blood glucose‡, n (%) 2 (2.2) 3 (3.3)
Compression therapy adopted upon inclusion
Short stretch elastic bandage, n (%) 43 (46.7) 36 (39.6)
Zinc oxide non-elastic bandage, n (%) 15 (16.3) 22 (24.2)
Combination of the above, n (%) 10 (10.9) 10 (11.0)
Zinc oxide elastic bandage, n (%) 22 (23.9) 20 (22.0)
Other, n (%) 2 (2.2) 3 (3.3)
∗Consisting of varicose vein surgery in all cases.
§ On the limb affected by target ulcer. All patients had multiple abnormalities.
¶ Vessel wall or valve alterations or endoluminal obstruction.
‡ 140 mg/dL upon inclusion, confirmed in one further determination.
n: number of patients; CVI: chronic venous insufficiency; IQR: interquartile range.
Kaplan–Meier plots for cumulative target ulcer heal- An alternative exploratory analysis was also per-
formed, in which ulcer healing events were attributeding over time are shown in Figure 1. Estimated time
to heal 25%, 50% (median) and 75% of the patients to the fixed visit dates as scheduled in the protocol
rather than to the actual dates when healing waswas 36, 64 and 90 days with mesoglycan versus 42,
70 and 136 days with placebo, while the estimated observed. Following this approach, the difference be-
tween treatments was again found to be significantrate of healing by the end of observation was 97%
versus 82%, respectively. The difference in favour of (p=0.02; p=0.03 after adjusting for baseline ulcer area)
and not time-dependent.mesoglycan was statistically significant (p<0.05) and
the corresponding relative risk for healing was 1.48 Out of 19 patients having a concomitant venous
ulcer upon inclusion (Table 1), 15 completed ob-(95% confidence interval [CI], 1.05 to 2.09). After ad-
justing for baseline ulcer area, the difference was still servation (10 mesoglycan, 5 placebo). Among these,
7 patients on mesoglycan and 1 on placebo achievedsignificant (p<0.05) and the relative risk for healing
with mesoglycan was 1.43 (CI, 1.01 to 2.04). No sig- complete healing of the concomitant ulcer by the
end of observation.nificant deviation from proportionality was detected
in the relative risk for healing over time, indicating The overall time-course for ulcer-associated pain
scores did not differ significantly according to treat-a relatively constant effect of mesoglycan over the
observation period. Treatment by centre interaction ment (p=0.27). The initial decrease in pain tended to
be greater on mesoglycan (from a mean [SD] baselinewas not significant.
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Fig. 1. Kaplan–Meier curves for cumulative ulcer healing over time, including all randomised patients. Numbers of patients that were on
observation at each time-point are shown at the bottom of the graph (M: mesoglycan; P: placebo).
score of 4.4 [3.0] to 1.7 [2.4] at the end of Week 3) than
on placebo (from 4.2 [2.8] to 2.1 [2.4], p<0.1.
Figure 2 shows the mean changes in SF-36 scores
Table 2. Adverse events (AE) reported during the observationthat occurred at the end of week 24±1 compared to
period, ordered by system-organ class.baseline, according to the healing status of target ulcer.
Healing was associated with improvements in each of Mesoglycan Placebo
(n=92) (n=91)the 8 health domains explored by the questionnaire,
whereas non-healed patients showed smaller im-
Skin Skin rash Skin rash∗provements or no change. Differences between healed Musculoskeletal Road accident trauma∗
CNS Headache, pruritus Drowsinessand non-healed patients were statistically significant
Gastrointestinal Epigastric pain(p<0.05) in 6 domains, i.e. bodily pain, general health,
Cardiovascular Congestive heart failure∗ Reversible cerebralvitality, social functioning, role limitation due to emo- ischaemia∗
Palpitations, orthostatic Cerebral stroke∗tional problems and mental health.
hypotensionReported adverse events are detailed in Table 2.
Episodes of faintingTotal adverse event incidence was 7/92 on mesoglycan Superficial
thrombophlebitis(8%) and 6/91 on placebo (7%). Only 2 events per
Respiratory Bronchopneumoniagroup were of serious nature (none being fatal), while
Haemorrhage Rectal bleeding∗those resulting in permanent treatment discontin- General Influenza
Total n of AE 8 7uation were 2 on mesoglycan and 4 on placebo. Most
Patients with AE 7 (8%) 6 (7%)of the events were considered unrelated to study
treatment. Their organ-system distribution (Table 2) ∗AE followed by permanent treatment discontinuation.
Serious AE are shown in italics.did not reveal clear treatment-related differences in
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Fig. 2. Self-assessment of health status by SF-36, according to the end-of-observation healing status of the target ulcer. Mean (SD) score
differences (end-of-observation – baseline) are shown for the 8 domains explored by the questionnaire. A positive difference means an
improvement in perceived health status. PF: Physical functioning; RP: Role-physical limitation; BP: Bodily pain; GH: General health; VT:
Vitality; SF: Social functioning; RE: Role-emotional limitation; MH: Mental health.
any event category. No injection site or systemic bleed- healing with mesoglycan was 1.48, or 1.43 in the
ing was observed in the mesoglycan group. adjusted analysis.
APTT was unaffected by treatment with meso- The healing rate achieved in the placebo group, 75%
glycan. No treatment-related difference was detected after 136 days, compared well with those recently
for any of the other laboratory tests. An on-treatment reported for venous ulcers managed with compression
platelet count of less than 100×103 l was detected in at reference wound care centres, 75% after 112 days21
one patient per group; the patient on mesoglycan had or 68% after 168 days.22 This suggests that compression
concomitant liver disease reported upon inclusion. and topical therapy was well implemented.
Healing of the target ulcer resulted in significant
improvements of patient-perceived health status, as
reflected by SF-36 scores. This confirmed the findings
Discussion of an earlier study using the Nottingham Health Pro-
file, in which the healing status of chronic venousIn this randomised, double-blind study, patients with
ulcers was found to be a major determinant of health-leg ulcers caused by CVI were treated with mesoglycan
related quality of life in the affected patients.23or placebo as an adjunct to established therapeutic
The mechanism by which ulcer healing was pro-measures (limb compression, topical wound care).
moted by treatment with mesoglycan remains to beCare was taken to enrol patients with ‘‘pure’’ venous
verified. Mesoglycan may counteract putative mech-ulcers – all had a diagnosis of CVI confirmed by duplex
anisms for venous ulceration10 through inhibition ofultrasound scanning and normal ankle/arm arterial
neutrophil adhesion and activation,4 preservation ofpressure index, while those with diabetes or other
endothelial barrier function,5 prevention of fibrin for-alternative causes of ulceration were excluded. The
mation2,3 and enhancement of fibrinolysis.6 An al-duration of observation, up until complete healing of
ternative or additional explanation is suggested bythe target ulcer or for 24±1 weeks, was long enough
recent reports highlighting the role of physiologicalto account for ulcer outcome rather than initial healing.
dermatan and heparan sulphate in wound healingTreatment with mesoglycan resulted in faster and
processes,24 including cutaneous wound repair.25more frequent ulcer healing. The estimated time to
The intramuscular followed by oral regimen ad-heal 75% of the patients was 90 days on mesoglycan
opted for the study reflected the use of mesoglycanversus 136 on placebo, while the estimated proportion
in current clinical practice. Since the ulcer healingof patients healed by the end of observation was 97.1%
advantage of mesoglycan relative to placebo was noton mesoglycan versus 81.8% on placebo. The difference
found to vary over the observation period, this wouldbetween treatments was statistically significant by in-
imply that the oral treatment contributed to the overalltent-to-treat analysis, and remained significant after
adjusting for baseline ulcer area. The relative risk of effect of mesoglycan. Previous reports have shown
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that fractions of sulphated polysaccharides are ab- options available for managing chronic venous ul-
ceration.sorbed after oral dosing11,12,26–28 and can produce in
vivo antithrombotic effects while generating barely
detectable anticoagulant activities.27,28
The safety profile of mesoglycan did not show im-
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A significant effect of sulphated polysaccharide
treatment on venous ulcer healing was previously
Appendixreported with sulodexide, a compound similar to me-
soglycan in composition. In a 2-month, open-label
In addition to the authors, the following investigatorsstudy the healing rate was 58% with intramuscular
participated in the Mesoglycan Venous Insufficiencyfollowed by oral sulodexide and compression therapy,
Group:versus 36% with compression alone.29
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reported with MPFF as an adjunct to compression rurgia Generale, Sezione di Chirurgia Vascolare, Os-
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of chronic venous ulcers in a significant proportion of bologico, Ospedale Garibaldi, Catania. E. Croce, A. Li
patients. Ulcer healing is an important positive out- Destri, G. Di Falco, Divisione di Chirurgia Vascolare,
come for health-related quality of life in the patients Ospedale Civile di Vittoria. S. M. Giulini, M. De Lucia,
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